Evicenter
MarkdownMedical informationP&T meetings
Lorundrostat (MLS-101)

Hypertension, in combination with other antihypertensive drugs

Also known as MT-4129
Launch
Not announced
Last updated
198 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatment

Heterogeneity of treatment effect

13 evidence topics · 7 sources

Summary
  • Lorundrostat: In Launch-HTN, the blood pressure effect of lorundrostat 50 mg was consistent across age, sex, race, body mass index, and number of background antihypertensive drugs. The placebo-adjusted change in office systolic blood pressure at week 6 was −8.8 mm Hg in participants taking 2 drugs and −9.0 mm Hg in those taking 3 or more. In a Launch-HTN analysis by chronic kidney disease (CKD) status, the placebo-adjusted reduction at week 12 was −12.2 mm Hg without CKD and −9.6 mm Hg with CKD stages 1 to 3; confirmed serum potassium above 6.0 mmol/L occurred in 3 (2.4%) participants with CKD and none without CKD. In the phase 2 Target-HTN trial, prespecified exploratory subgroups showed larger reductions in participants with a body mass index above 30 than in those with a body mass index of 25 to 30, and attenuated reductions in participants not taking a diuretic; participants with nonsuppressed plasma renin (exploratory cohort 2) had a reduction similar to those with suppressed renin at 100 mg. In Explore-OSA, participants with obesity and moderate-to-severe obstructive sleep apnea had a placebo-adjusted office systolic reduction of 10.1 mm Hg in the parallel-arm analysis.
  • Class evidence: ICER reported consistent baxdrostat effects across all prespecified subgroups in BaxHTN and Bax24, similar aldosterone synthase inhibitor effects in participants taking two versus three or more background drugs, and no differential blood pressure lowering by mineralocorticoid antagonists between resistant and non-resistant hypertension. In a randomized crossover trial in resistant hypertension, spironolactone lowered blood pressure most across the distribution of baseline plasma renin, with a margin of superiority many-fold greater at the lower end, and plasma renin and the aldosterone-to-renin ratio predicted the home systolic response.
  • Limits of the evidence: The pivotal aldosterone synthase inhibitor trials excluded people with advanced CKD. ICER reports hearing that differences in treatment effect by race or ethnicity are small and not likely to be clinically significant. Target-HTN subgroup analyses were exploratory.
Lorundrostat by chronic kidney disease stage in Launch-HTN: placebo-adjusted change at week 12
CKD stageLorundrostat 50 mg participantsPlacebo-adjusted AOSBP change, mm Hg (95% CI)Week 12 % with AOSBP <130 mmHg, lorundrostat 50 mg
No CKD“N=406”“-12.2 (-17.1, -7.3)”“48.0”
Stage 1“N=58”“-10.6 (-18.6, -2.6)”“50.6”
Stage 2“N=31”“-7.6 (-16.5, 1.4)”“28.4”
Stage 3“N=38”“-10.1 (-21.1, 1.0)”“47.0”